ivonescimab

all catalysts(0)

nothing on the calendar yet

News(10)

• AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
  Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene t…
  biospace · 4d ago
• STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
  AstraZeneca is teaming up with Summit Therapeutics to test its PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s antibody-drug conjugates.
  stat · 5d ago
• Summit snags $2B investment from AstraZeneca, clearing financial overhang
  The all-stock deal gives Summit Therapeutics enough money to see through Phase 3 trials for the PD-1/VEGF bispecific ivonescimab—but keeps the asset fully in-house without giving up licensing rights.
  biospace · 5d ago
• AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
  The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.
  biopharma_dive · 5d ago
• AstraZeneca scales Summit’s PD-1xVEGF strategy with $2B investment to fuel ADC combos
  AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab in combination with antibody-drug conjugates (ADCs). The newly minted pa…
  fiercebiotech · 6d ago
• Compass vows to press on with FDA application despite new trial request
  Citing the urgent unmet need for patients with advanced biliary tract cancer, Compass Therapeutics will continue to seek an approval path for its drug after the FDA recommended the biotech conduct…
  biospace · 12d ago
• China plans to transform biotech sector into $522B powerhouse by 2030
  A new five-year biotech plan has been released by the Chinese government, revealing ambitious goals such as achieving five blockbuster medicines on the global markets in that time.
  biospace · 16d ago
• WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
  The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.
  biopharma_dive · 19d ago
• Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
  As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.
  biopharma_dive · 20d ago
• Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
  BioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place in South Korea. These companies and their partners have all shared new fi…
  biospace · 20d ago